预约演示

Sanofi joins anti-TL1A frenzy via partnership with Teva

2023-10-04

交易

临床2期引进/卖出临床1期

Sanofi agreed to pay €469 million ($492 million) upfront for rights to co-develop and jointly market Teva’s anti-TL1A candidate TEV-48574 for inflammatory bowel disease (IBD), the companies announced Wednesday. A deal had been expected after sources said in May that Teva was seeking a partner for the experimental drug having previously highlighted it as one of its "key pipeline assets."

TEV-48574 is currently in Phase IIb studies for the treatment of ulcerative colitis and Crohn's disease. “Anti-TL1As are a promising class of therapies, and we believe that TEV’574 could emerge as a best-in-class option,” remarked Sanofi CEO Paul Hudson.

Under the agreed terms, Sanofi will lead Phase III programme for TEV-48574, with both companies equally sharing the development costs and net profits and losses in major markets, with other markets subject to a royalty arrangement. Along with the upfront payment, Teva is eligible for milestones of up to €940 million ($986 million), with the Israeli drugmaker leading commercialisation in Europe, Israel and specified other countries, while Sanofi will head-up marketing in North America, Japan, other parts of Asia and the rest of the world.

Interest in the anti-TL1A class has increased since Merck & Co. agreed in April to put up $10.8 billion to buy Prometheus Biosciences primarily to get its hands on PRA023. Meanwhile, Pfizer and Roivant Sciences are developing a similar drug, dubbed RVT-3101, that is in mid-stage testing.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构